Eisai US
4523
Performance
About Eisai US
Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., dedicated to human health care (hhc) by prioritizing the needs of patients and their families. Based in New Jersey, Eisai focuses on developing innovative therapies primarily in the fields of oncology and neurology, particularly addressing dementia-related and neurodegenerative diseases. The company integrates discovery, development, and marketing efforts across various locations, including Massachusetts and Pennsylvania for research and Maryland and North Carolina for global demand chain operations.
Recent News
What’s the Deal with Alzheimer’s Disease and Amyloid?
Effect of ‘Gamechanger’ Alzheimer’s Drugs ‘Trivial’, Review Concludes
Shanghai Start-Up Launches to Develop Trispecific Antibodies
CMS's Medicare Price Negotiations Start Round Three
Diagnostics Lag Is Holding Back New Therapies, Says Study
Leqembi Starts to Deliver for Eisai and Biogen
Could Alzheimer's Be Predicted with a Finger-Prick Test?
The New Gold Rush in Brain Science
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
FDA Kicks Off Review of Takeda's Narcolepsy Hopeful
Eisai Gains Henlius Therapy; LB Pharma Snags $100M in Funding
Biogen's Stock Slumps as Biosimilars Hit MS Sales and Alzheimer Setbacks Loom
Harmeier Returns to Lead Roche Venture Fund
Recent Deals
No recent deals for this company.
